Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Eva VersteijneJacob L van DamMustafa SukerQuisette P JanssenKarin GroothuisJanine M Akkermans-VogelaarMarc G H BesselinkBert A BonsingJeroen BuijsenOlivier R C BuschGeert-Jan M CreemersRonald M van DamFerry A L M EskensSebastiaan FestenJan Willem B de GrootBas Groot KoerkampIgnace H de HinghMarjolein Y V HomsJeanin E van HooftEmile D KerverSaskia A C LuelmoKaren J NeelisJoost NuyttensGabriel M R M PaardekooperGijs A PatijnMaurice J C van der SangenJudith De Vos-GeelenJohanna W WilminkAeilko H ZwindermanCornelis J PuntGeertjan van TienhovenCasper H J van Eijcknull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.